- Investing Ideas
- U.S. Pharmaceuticals & Biotech Blue chip stocks
U.S. Pharmaceuticals & Biotech Blue chip stocks
Results
18
18 companies
Charles River Laboratories International
Market Cap: US$10.2b
Charles River Laboratories International, Inc.
CRL
US$215.75
7D
16.6%
1Y
43.8%
Ionis Pharmaceuticals
Market Cap: US$13.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$81.18
7D
9.5%
1Y
104.0%
Axsome Therapeutics
Market Cap: US$12.2b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$241.67
7D
-3.5%
1Y
133.8%
Elanco Animal Health
Market Cap: US$12.2b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.57
7D
1.4%
1Y
71.9%
ICON
Market Cap: US$12.3b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$169.86
7D
16.3%
1Y
17.5%
Natera
Market Cap: US$37.3b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$261.91
7D
13.2%
1Y
55.9%
Insmed
Market Cap: US$22.6b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$103.38
7D
7.9%
1Y
3.9%
BioMarin Pharmaceutical
Market Cap: US$11.1b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$59.00
7D
7.9%
1Y
6.9%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$512.65
7D
1.4%
1Y
70.5%
Viatris
Market Cap: US$18.7b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.33
7D
6.2%
1Y
81.2%
Alnylam Pharmaceuticals
Market Cap: US$39.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$291.37
7D
4.8%
1Y
-9.7%
Jazz Pharmaceuticals
Market Cap: US$14.2b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$230.02
7D
2.4%
1Y
115.2%
BeOne Medicines
Market Cap: US$30.6b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$279.89
7D
3.6%
1Y
16.0%
Neurocrine Biosciences
Market Cap: US$16.5b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$168.52
7D
6.5%
1Y
34.4%
Royalty Pharma
Market Cap: US$31.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$56.23
7D
6.2%
1Y
56.8%
Merck
Market Cap: US$309.8b
Operates as a healthcare company worldwide.
MRK
US$128.66
7D
13.0%
1Y
62.7%
Krystal Biotech
Market Cap: US$10.6b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$372.25
7D
7.0%
1Y
168.0%
Gilead Sciences
Market Cap: US$153.8b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$127.88
7D
3.3%
1Y
15.6%